Details for Patent: 11,357,820
✉ Email this page to a colleague
Which drugs does patent 11,357,820 protect, and when does it expire?
Patent 11,357,820 protects MOUNJARO, MOUNJARO (AUTOINJECTOR), and ZEPBOUND (AUTOINJECTOR), and is included in two NDAs.
This patent has forty-one patent family members in thirty-two countries.
Summary for Patent: 11,357,820
Title: | GIP/GLP1 agonist compositions |
Abstract: | A composition of tirzepatide, comprising an agent selected from NaCl and propylene glycol; and dibasic sodium phosphate is provided. |
Inventor(s): | Corvari; Vincent John (Carmel, IN), Minie; Christopher Sears (Zionsville, IN), Mishra; Dinesh Shyamdeo (Carmel, IN), Qian; Ken Kangyi (Carmel, IN) |
Assignee: | Eli Lilly and Company (Indianapolis, IN) |
Application Number: | 16/441,329 |
Patent Claim Types: see list of patent claims | Use; Composition; Device; |
Recent additions to Drugs Protected by US Patent 11,357,820
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Type | RLD | Patent No. | Product | Substance | Delist Req. | Patent Expiration | Usecode | Patented / Exclusive Use |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Eli Lilly And Co | ZEPBOUND | tirzepatide | SOLUTION | 217806 | Mar 28, 2024 | RX | Yes | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Type | >RLD | >Patent No. | >Product | >Substance | >Delist Req. | >Patent Expiration | >Usecode | >Patented / Exclusive Use |
Drugs Protected by US Patent 11,357,820
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Eli Lilly And Co | MOUNJARO | tirzepatide | SOLUTION;SUBCUTANEOUS | 215866-007 | Jul 28, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | |||
Eli Lilly And Co | MOUNJARO | tirzepatide | SOLUTION;SUBCUTANEOUS | 215866-008 | Jul 28, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | |||
Eli Lilly And Co | MOUNJARO | tirzepatide | SOLUTION;SUBCUTANEOUS | 215866-009 | Jul 28, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | |||
Eli Lilly And Co | MOUNJARO | tirzepatide | SOLUTION;SUBCUTANEOUS | 215866-010 | Jul 28, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | |||
Eli Lilly And Co | MOUNJARO | tirzepatide | SOLUTION;SUBCUTANEOUS | 215866-011 | Jul 28, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | |||
Eli Lilly And Co | MOUNJARO | tirzepatide | SOLUTION;SUBCUTANEOUS | 215866-012 | Jul 28, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,357,820
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Argentina | 115542 | ⤷ Try a Trial | |||
Australia | 2019289110 | ⤷ Try a Trial | |||
Australia | 2022279524 | ⤷ Try a Trial | |||
Brazil | 112020023452 | ⤷ Try a Trial | |||
Canada | 3103469 | ⤷ Try a Trial | |||
Chile | 2020003359 | ⤷ Try a Trial | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |